{"id":8062,"date":"2025-07-23T10:31:36","date_gmt":"2025-07-23T07:31:36","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8062"},"modified":"2025-07-23T10:31:36","modified_gmt":"2025-07-23T07:31:36","slug":"scientific-summary-baxhtn-phase-3-trial-baxdrostat-for-uncontrolled-hypertension","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/scientific-summary-baxhtn-phase-3-trial-baxdrostat-for-uncontrolled-hypertension\/","title":{"rendered":"Scientific Summary: BaxHTN Phase 3 Trial \u2013 Baxdrostat for Uncontrolled Hypertension"},"content":{"rendered":"<p><span>Scientific Summary: BaxHTN Phase 3 Trial \u2013 Baxdrostat for Uncontrolled Hypertension<\/span><\/p>\n<p><span>Highlighted by Medical News Media \u2013 To be presented at ESC Congress 2025.<\/span><\/p>\n<p><span>Published: July 14, 2025<\/span><br \/>\n<span>phase-3-results.<\/span><\/p>\n<p><span>Key Findings:<\/span><br \/>\n<span>1. Study Design:<\/span><br \/>\n<span>The BaxHTN trial was a phase 3, randomized, double-blind, placebo-controlled, multicenter study involving 796 patients with uncontrolled or treatment-resistant hypertension.<\/span><br \/>\n<span>2. Patient Population:<\/span><br \/>\n<span>\u2022 Uncontrolled hypertension: patients on 2 antihypertensive agents.<\/span><br \/>\n<span>\u2022 Resistant hypertension: patients on 3 or more antihypertensives, including a diuretic.<\/span><br \/>\n<span>Participants were randomized in a 1:1:1 ratio to receive:<\/span><br \/>\n<span>\u2022 Baxdrostat 2 mg<\/span><br \/>\n<span>\u2022 Baxdrostat 1 mg<\/span><br \/>\n<span>\u2022 Placebo<\/span><br \/>\n<span>3. Primary Outcome:<\/span><br \/>\n<span>\u2022 Baxdrostat at both doses (1 mg and 2 mg) significantly reduced mean seated systolic blood pressure (SBP) compared to placebo at 12 weeks.<\/span><br \/>\n<span>4. Secondary Endpoints:<\/span><br \/>\n<span>\u2022 All secondary endpoints were met, showing robust efficacy across multiple BP measures.<\/span><br \/>\n<span>5. Safety:<\/span><br \/>\n<span>\u2022 Baxdrostat demonstrated a favorable safety profile throughout the 12-week study period.<\/span><br \/>\n<img decoding=\"async\" class=\"an1\" draggable=\"false\" src=\"https:\/\/fonts.gstatic.com\/s\/e\/notoemoji\/16.0\/1f517\/72.png\" alt=\"\ud83d\udd17\" data-emoji=\"\ud83d\udd17\" aria-label=\"\ud83d\udd17\" \/><span>\u00a0<\/span><a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/baxhtn-\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/baxhtn-&amp;source=gmail&amp;ust=1753341956417000&amp;usg=AOvVaw1lyh1HDLZlPKPT5bZXFCKw\" rel=\"noopener\">https:\/\/www.astrazeneca.com\/<wbr \/>media-centre\/press-releases\/<wbr \/>2025\/baxhtn-<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scientific Summary: BaxHTN Phase 3 Trial \u2013 Baxdrostat for Uncontrolled Hypertension Highlighted by Medical News Media \u2013 To be presented at ESC Congress 2025. Published: July 14, 2025 phase-3-results. Key Findings: 1. Study Design: The BaxHTN trial was a phase 3, randomized, double-blind, placebo-controlled, multicenter study involving 796 patients with uncontrolled or treatment-resistant hypertension. 2. [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8062","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8062"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8062\/revisions"}],"predecessor-version":[{"id":8063,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8062\/revisions\/8063"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}